New hope for kids with lupus: injectable drug under study
NCT ID NCT04179032
First seen Oct 31, 2025 · Last updated Apr 29, 2026 · Updated 23 times
Summary
This study looks at how a drug called belimumab works in children aged 5 to 17 with lupus. The drug is given as a shot under the skin, along with standard treatments. The goal is to check the drug's safety and how the body processes it, to help manage lupus symptoms long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Rosario, 2000, Argentina
-
GSK Investigational Site
Berlin, 13353, Germany
-
GSK Investigational Site
Saint Augustin, 53757, Germany
-
GSK Investigational Site
Kagoshima, 890-8520, Japan
-
GSK Investigational Site
Kanagawa, 216-8511, Japan
-
GSK Investigational Site
San Luis Potosí City, 78213, Mexico
-
GSK Investigational Site
Rotterdam, 3015 GJ, Netherlands
-
GSK Investigational Site
Barcelona, 08950, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
Conditions
Explore the condition pages connected to this study.